Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones

Luis J. del Valle; Lidia Flores; Martha Vargas; Ruth García-de-la-Guarda; Ruth L. Quispe; Zoila B. Ibañez; Débora Alvarado; Pablo Ramírez; Joaquim Ruiz

doi:10.1016/j.ijid.2009.07.025

Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones

Luis J. del Valle, Lidia Flores, Martha Vargas, Ruth García-de-la-Guarda, Ruth L. Quispe, Zoila B. Ibañez, Débora Alvarado, Pablo Ramírez, Joaquim Ruiz

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

Objectives: To analyze the sequence of the region involved in the development of quinolone resistance of the gyrA and parC genes in a series of Bartonella bacilliformis isolates recovered prior to the introduction of quinolones, as well as one clinical isolate recovered in the 1970s, establishing the susceptibility levels to nalidixic acid and ciprofloxacin. Methods: Five B. bacilliformis were studied: four isolated before 1957, prior to the introduction of quinolones in clinical practice. The remaining strain was isolated in 1977. A fragment of the gyrA and parC genes was amplified and sequenced. Susceptibility to nalidixic acid and ciprofloxacin was established by the E-test method. Results: All the strains were resistant to nalidixic acid (minimum inhibitory concentration (MIC) >256 mg/l). Three isolates presented decreased susceptibility to ciprofloxacin and two were highly resistant (MIC >32 mg/l). All the strains presented an Ala at position 91 of GyrA and position 85 of ParC. Conclusions: B. bacilliformis presents a constitutive resistance to quinolones, which may be related to the presence of Ala at position 91 of GyrA and 85 of ParC. These results advise against the current clinical guidelines recommending the use of ciprofloxacin to treat bartonellosis in some countries of the Andean area.

Original language	English
Pages (from-to)	e506-e510
Journal	International Journal of Infectious Diseases
Volume	14
Issue number	6
DOIs	https://doi.org/10.1016/j.ijid.2009.07.025
State	Published - Jun 2010

Bibliographical note

Funding Information:
This work was partially funded by the AECID (Agencia Española de Cooperación Internacional para el Desarrollo) grant numbers A/3795/05, A/4892/06, A/9727/07 A/4817/06; ACCD (Agència Catalana de Cooperació al Desenvolupament, Generalitat de Catalunya) grant U2006; CCD-UPC (Centre de Cooperació per al Desenvolupament, Universitat Politècnica de Catalunya) to LJdV; and by the CONCYTEC (Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica, Perú) grant 189-2005-CONCYTEC-OAJ. JR's research is supported by grant CP05/0130 of the FIS (Fondo de Investigaciones Sanitarias).

Keywords

Bartonella bacilliformis
Carrion's disease
Quinolones
Resistance
gyrA
parC

Access to Document

10.1016/j.ijid.2009.07.025

Cite this

@article{194094acd26e4603b06634e6866a17e0,

title = "Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones",

abstract = "Objectives: To analyze the sequence of the region involved in the development of quinolone resistance of the gyrA and parC genes in a series of Bartonella bacilliformis isolates recovered prior to the introduction of quinolones, as well as one clinical isolate recovered in the 1970s, establishing the susceptibility levels to nalidixic acid and ciprofloxacin. Methods: Five B. bacilliformis were studied: four isolated before 1957, prior to the introduction of quinolones in clinical practice. The remaining strain was isolated in 1977. A fragment of the gyrA and parC genes was amplified and sequenced. Susceptibility to nalidixic acid and ciprofloxacin was established by the E-test method. Results: All the strains were resistant to nalidixic acid (minimum inhibitory concentration (MIC) >256 mg/l). Three isolates presented decreased susceptibility to ciprofloxacin and two were highly resistant (MIC >32 mg/l). All the strains presented an Ala at position 91 of GyrA and position 85 of ParC. Conclusions: B. bacilliformis presents a constitutive resistance to quinolones, which may be related to the presence of Ala at position 91 of GyrA and 85 of ParC. These results advise against the current clinical guidelines recommending the use of ciprofloxacin to treat bartonellosis in some countries of the Andean area.",

keywords = "Bartonella bacilliformis, Carrion's disease, Quinolones, Resistance, gyrA, parC",

author = "{del Valle}, {Luis J.} and Lidia Flores and Martha Vargas and Ruth Garc{\'i}a-de-la-Guarda and Quispe, {Ruth L.} and Iba{\~n}ez, {Zoila B.} and D{\'e}bora Alvarado and Pablo Ram{\'i}rez and Joaquim Ruiz",

note = "Funding Information: This work was partially funded by the AECID (Agencia Espa{\~n}ola de Cooperaci{\'o}n Internacional para el Desarrollo) grant numbers A/3795/05, A/4892/06, A/9727/07 A/4817/06; ACCD (Ag{\`e}ncia Catalana de Cooperaci{\'o} al Desenvolupament, Generalitat de Catalunya) grant U2006; CCD-UPC (Centre de Cooperaci{\'o} per al Desenvolupament, Universitat Polit{\`e}cnica de Catalunya) to LJdV; and by the CONCYTEC (Consejo Nacional de Ciencia, Tecnolog{\'i}a e Innovaci{\'o}n Tecnol{\'o}gica, Per{\'u}) grant 189-2005-CONCYTEC-OAJ. JR's research is supported by grant CP05/0130 of the FIS (Fondo de Investigaciones Sanitarias). ",

year = "2010",

month = jun,

doi = "10.1016/j.ijid.2009.07.025",

language = "Ingl{\'e}s",

volume = "14",

pages = "e506--e510",

journal = "International Journal of Infectious Diseases",

issn = "1201-9712",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones

AU - del Valle, Luis J.

AU - Flores, Lidia

AU - Vargas, Martha

AU - García-de-la-Guarda, Ruth

AU - Quispe, Ruth L.

AU - Ibañez, Zoila B.

AU - Alvarado, Débora

AU - Ramírez, Pablo

AU - Ruiz, Joaquim

N1 - Funding Information: This work was partially funded by the AECID (Agencia Española de Cooperación Internacional para el Desarrollo) grant numbers A/3795/05, A/4892/06, A/9727/07 A/4817/06; ACCD (Agència Catalana de Cooperació al Desenvolupament, Generalitat de Catalunya) grant U2006; CCD-UPC (Centre de Cooperació per al Desenvolupament, Universitat Politècnica de Catalunya) to LJdV; and by the CONCYTEC (Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica, Perú) grant 189-2005-CONCYTEC-OAJ. JR's research is supported by grant CP05/0130 of the FIS (Fondo de Investigaciones Sanitarias).

PY - 2010/6

Y1 - 2010/6

N2 - Objectives: To analyze the sequence of the region involved in the development of quinolone resistance of the gyrA and parC genes in a series of Bartonella bacilliformis isolates recovered prior to the introduction of quinolones, as well as one clinical isolate recovered in the 1970s, establishing the susceptibility levels to nalidixic acid and ciprofloxacin. Methods: Five B. bacilliformis were studied: four isolated before 1957, prior to the introduction of quinolones in clinical practice. The remaining strain was isolated in 1977. A fragment of the gyrA and parC genes was amplified and sequenced. Susceptibility to nalidixic acid and ciprofloxacin was established by the E-test method. Results: All the strains were resistant to nalidixic acid (minimum inhibitory concentration (MIC) >256 mg/l). Three isolates presented decreased susceptibility to ciprofloxacin and two were highly resistant (MIC >32 mg/l). All the strains presented an Ala at position 91 of GyrA and position 85 of ParC. Conclusions: B. bacilliformis presents a constitutive resistance to quinolones, which may be related to the presence of Ala at position 91 of GyrA and 85 of ParC. These results advise against the current clinical guidelines recommending the use of ciprofloxacin to treat bartonellosis in some countries of the Andean area.

AB - Objectives: To analyze the sequence of the region involved in the development of quinolone resistance of the gyrA and parC genes in a series of Bartonella bacilliformis isolates recovered prior to the introduction of quinolones, as well as one clinical isolate recovered in the 1970s, establishing the susceptibility levels to nalidixic acid and ciprofloxacin. Methods: Five B. bacilliformis were studied: four isolated before 1957, prior to the introduction of quinolones in clinical practice. The remaining strain was isolated in 1977. A fragment of the gyrA and parC genes was amplified and sequenced. Susceptibility to nalidixic acid and ciprofloxacin was established by the E-test method. Results: All the strains were resistant to nalidixic acid (minimum inhibitory concentration (MIC) >256 mg/l). Three isolates presented decreased susceptibility to ciprofloxacin and two were highly resistant (MIC >32 mg/l). All the strains presented an Ala at position 91 of GyrA and position 85 of ParC. Conclusions: B. bacilliformis presents a constitutive resistance to quinolones, which may be related to the presence of Ala at position 91 of GyrA and 85 of ParC. These results advise against the current clinical guidelines recommending the use of ciprofloxacin to treat bartonellosis in some countries of the Andean area.

KW - Bartonella bacilliformis

KW - Carrion's disease

KW - Quinolones

KW - Resistance

KW - gyrA

KW - parC

UR - http://www.scopus.com/inward/record.url?scp=77952240900&partnerID=8YFLogxK

U2 - 10.1016/j.ijid.2009.07.025

DO - 10.1016/j.ijid.2009.07.025

M3 - Artículo

C2 - 19969497

AN - SCOPUS:77952240900

SN - 1201-9712

VL - 14

SP - e506-e510

JO - International Journal of Infectious Diseases

JF - International Journal of Infectious Diseases

IS - 6

ER -

Bartonella bacilliformis, endemic pathogen of the Andean region, is intrinsically resistant to quinolones

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this